Innogenetics completes and strengthens top management

14-Sep-2005

Innogenetics announced that it has appointed several new members of the Management Committee to further reinforce its management team. These new appointments include Ingrid De Wilde who has been appointed as Vice-President Human Resources; Wolfgang Seidel, who joined the Company as Vice-President business development and Licensing; and Christian Matton, who will function as Vice-President Legal and Intellectual Property.

Ingrid De Wilde holds a Law degree from the University of Gent (1979), after which she went on to obtain a Master's degree in Tax Management (VLEKHO) and in Business Administration (Cepac, Solvay). She has substantial experience both in national and international Human Resources environments for companies such as UCB and AGFA Europe. Before joining Innogenetics, she held the position of Director Compensation & Benefits, Global Staffing at GlaxoSmithKline Biologicals.

Wolfgang Seidel studied Chemistry and Biology at the University of Münster, Germany, where he obtained his doctorate in Organic Chemistry in 1980. After a postdoctorate in Zurich, he joined Bayer AG as clinical chemist in 1981, and was subsequently appointed project manager for international clinical studies. In 1988, he became Director of Bayer's therapeutic monoclonal antibody development program in Berkeley, California. Since 1992 Wolfgang fulfilled several functions in Bayer's International Pharmaceutical Sales & Marketing Organization, before becoming responsible for the German Biological Products business. Until recently, he was a member of the Bayer Vital Executive Committee. He adds substantial marketing and sales experience to the Innogenetics team. He has also been a member of the "Working Group Blood" of the German Ministry of Health since 1998.

Christian Matton obtained a Master's Degree in Law and a postgraduate degree in European Law at the University of Gent. After working for several years at the Storme-Leroy-Van Parys Law firm in Gent and Brussels, he joined the Belgian pharmaceutical and chemical company UCB in Brussels in 1993 as member of its central Legal Department. In 2000, he became the General Counsel for the worldwide pharma activities of the UCB Group as well as the group's global antitrust compliance counsel. He was involved in important international projects of the group in Europe and China. Subsequently, he was appointed Vice-President and General Counsel Europe Asia Pacific and Africa Middle East. He is also a member of several think tanks on pharmaceutical law, and a regular speaker at international legal conferences in London and Brussels.

Frank Morich, CEO of Innogenetics expressed his enthusiasm about the newly strengthened and completed management team. "We are very pleased to count on the proven experience of Ingrid De Wilde in the life science industry. Her international background will particularly contribute to the further successful development of our organization and its critical human capital. The experience of Wolfgang Seidel will be an important asset to increase access to our diagnostic product portfolio through strategic partnerships. Wolfgang will also be involved in the contacts with pharmaceutical companies for our therapeutics projects. Finally, the know-how of Christian Matton will be crucial in successfully managing the valorization and protection of Innogenetics' rich intellectual patent portfolio. Also, his broad legal expertise should prove invaluable."

https://www.bionity.com/en/news/48889/innogenetics-completes-and-strengthens-top-management.html